TSLA
Tesla
-- 462.280 NVDA
NVIDIA
-- 140.220 PLTR
Palantir
-- 82.380 MSTR
MicroStrategy
-- 358.180 AMD
Advanced Micro Devices
-- 126.290 
PLUG Lowered To HOLD, Losses Still Predicted In 2025. ESPR Reiterated Strong Buy, Profitable In 2025
$Plug Power (PLUG.US)$We lowered our rating to HOLD based on earnings growth is still not enough to gain profits. We believe Trump will win the 2024 election, and that will put pressure on Plug Power. End of 2025 PLUG is estimated to have a loss of ($-0.57) a share. We expect more dilution will also be needed.
Esperion $Esperion Therapeutics (ESPR.US)$ We reiterate Strong Buy rating. Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, an estimated 21 Million Americans are Statin intolerant, we see continued prescription growth & expect over 500,000 patients by 2026 which will generate over $2 billion in yearly revenues. Our 2025 yearly earnings estimate is $0.29 to $0.36 per share. After discussing with Jefferies analyst Dennis Ding we think Esperion has a strong chance of being acquired in the near future, we think Esperion could easily fetch $2 billion, around $10 per share.
Recent remarks from Jefferies:
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Huang he : Completely correct, based on this forecast, I anticipate the possibility of bankruptcy in 2026.